THE
INDEPENDENT
STUDENT
N E W S PA P E R
OF
TUFTS
UNIVERSITY
T HE T UFTS DAILY
E S T. 1 9 8 0
tuftsdaily.com
Monday, March 15, 2021
VOLUME LXXXI, ISSUE 24
Uncertainty around Tufts’ vaccination plans persists as Massachusetts continues through Phase 2 of vaccine rollout by Sarah Sandlow Deputy News Editor
In a Feb. 18 email to the Tufts community, Michael Jordan, university infection control health director, explained Tufts’ plans to continue with Massachusetts’ vaccine rollout plan, which entered Phase 2, Group 2 that day. This group includes individuals 65 years and older, individuals with two or more qualifying medical conditions and those living or working in affordable senior housing. However, the university did not have — and still does not have — vaccines to offer to those who fell into this group, meaning qualifying individuals have had to find other means to get vaccinated outside of Tufts. Now that Phase 3, which includes the majority of the student community and the general public, is approaching, uncertainty about how Tufts will distribute the vaccine persists. Marie Caggiano, medical director of Health Service, told the Daily in an email that Tufts has received a very limited number of vaccines to distribute to the community. Massachusetts is currently prioritizing other distribution sites, such as regional vaccine sites and pharmacies, before it distributes supplies to colleges and universities. “We have vaccinated a small number of individuals to date (approximately 100),” Caggiano said.
NICHOLAS PFOSI / THE TUFTS DAILY ARCHIVES
Tufts Medical Center is pictured on Aug. 28, 2014. Those individuals, per the state’s guidelines, include health care workers, first responders and those who met the relevant state age requirements for each phase. First responders have also received their vaccines through the cities of Somerville and Worcester.
However, Caggiano said that if Tufts does receive vaccines in the future, it is prepared to administer them. “We are continuing to plan for the potential of administering [the] vaccine once it becomes available to us in larger quantities,” Caggiano said.
Caggiano said that due to both the evolving nature of the state’s vaccination rollout and continued public health guidance, there is generally much uncertainty surrounding Tufts’ vaccination plans. The Feb. 18 email emphasized that although Massachusetts
had moved into Phase 2, Group 2 of vaccinations, Tufts did not have vaccines available to host an on-campus clinic. Eligible members of the community were encouraged to find nearby pharmacies or mass vaccination sites. see VACCINES, page 2
Testing anomaly reported as Broad Institute introduces more sensitive testing by Alexander Janoff Deputy News Editor
The Tufts Daily uncovered an anomaly in university reporting on the Daily’s COVID-19 dashboard when the number of new cases on the Medford/ Somerville campus declined by 20 and the number of new tests on the Medford/Somerville campus declined by 13 on Feb. 10. New case metrics for the dashboard are determined by subtracting the prior day’s cumulative number of unique
positive cases from the current day’s cumulative number of unique positive cases. Since the cumulative number of unique positive cases should only ever increase, the Daily’s calculated new case metric should only ever be positive. According to Michael Jordan, university infection control health director, and Chris Sedore, vice president for information technology and chief information officer, the anomaly occurred because the Broad Institute, the organization responsible for per-
forming COVID-19 surveillance testing for Tufts and many other schools in the region, launched a new version of the test it uses to detect COVID-19. “This new version tests for two distinct genes of the SARS-CoV-2 virus, specifically, the N1 and N2 genes,” Jordan and Sedore wrote in an email to the Daily. “By looking at two regions of the virus, the new assay has increased sensitivity compared to prior versions which only tested for the N2 gene.” An assay is an analytic procedure in lab sciences that is used
to determine the presence or amount of a target substance. The Broad Institute further explained its procedural development in a statement to the Daily. “Late last month, the Broad testing center upgraded our high-scale testing to double our capacity and increase the robustness of our assay,” the statement said. “After two weeks’ worth of data from the upgrade, working with the MA Department of Public Health, we adjusted the interpretation thresholds that we use to call a test ‘positive.’”
Jordan and Sedore further explained the reason behind the Broad Institute’s change in test classifications. They said that a test must detect the presence of both the N1 and N2 genes to be deemed positive, an increase in criteria compared to the previous threshold, which required the presence of just one of the genes. “Based on clinical and epidemiological data from case investigations, the Massachusetts Department of Public Health (MPDH) in collaborasee TEST, page 2
GRAPHIC CREDIT: KAYLA DRAZAN, ASLI KOCAK, ANNABEL NIED
EDITORIAL / page 10
PHOTOS / page 6
GRAPHICS / page 7
Using what we’ve learned this year to promote change
Snapshots of the past year
March 2020 – March 2021 at Tufts
NEWS
1
FEATURES
3
ARTS & POP CULTURE
5
FUN & GAMES OPINION SPORTS
9 10 BACK